BF Biosciences enters contract manufacturing deal with Lucky Core Industries

Agreement covers production of Esopase IV 40 mg and Etipro IV 40 mg

BF Biosciences Limited (BFBL), a subsidiary of Ferozsons Laboratories Limited, has signed a contract manufacturing and supply agreement with Lucky Core Industries Limited (LCI). 

The agreement involves the production of two pharmaceutical products: Esopase IV 40 mg and Etipro IV 40 mg.

This development was communicated by Ferozsons Laboratories in accordance with Section 96 of the Securities Act, 2015, and Clause 5.6.1(a) of PSX Regulations. 

The company requested that the relevant information be disseminated to the TREC Holders of the Pakistan Stock Exchange. 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Must Read

PIA to launch inaugural flight to Gwadar airport on January 20

The project aims to make Gwadar an important hub in Balochistan, supporting CPEC’s goals of better connectivity and economic growth